Surya Pharmaceutical Peer Comparison
NSE: SURYAPHARM | BSE: 532516
₹0.16
₹-0.01
(-5.88%)
As on 14-Sep-2015IST
Market cap
₹3 Cr
Revenue (TTM)
₹3 Cr
P/E Ratio
0
P/B Ratio
-0
Div. Yield
0 %
Edit
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
3 | 33,911 | 29,031 | 28,149 | 27,692 |
Revenue (₹ Cr) |
3 | 3,564 | 1,936 | 1,462 | 9,205 |
Net Profit (₹ Cr) |
258.68 | 414.00 | 288.22 | 387.35 | -371.81 |
Net Margin (%) |
9,933.76 | 11.23 | 14.79 | 26.01 | -3.93 |
RoE (%) |
-- | 8.38 | 29.77 | 25.18 | -3.85 |
Price to Earnings |
0.01 | 82.91 | 100.73 | 72.88 | -- |
Price-To-Book |
0.00 | 6.74 | 21.63 | 16.31 | 3.46 |
Income Statement (₹ Cr)
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Operating Revenue
|
90.44 | 5,609.42 | 37.09 | 55.51 | -- |
|
Total Income
|
91.42 | 5,663.42 | 37.09 | 55.99 | -- |
|
Total Expenditure
|
273.11 | 3,549.74 | 27.46 | 50.88 | -- |
|
EBITDA
|
-182.67 | 2,059.68 | 9.63 | 4.63 | -- |
|
Depreciation
|
68.35 | 122.14 | 3.08 | 0.90 | -- |
|
EBIT
|
-251.01 | 1,937.54 | 6.55 | 3.73 | -- |
|
Interest
|
221.61 | 215.37 | 2.58 | 1.11 | -- |
|
Other Income
|
0.97 | 54.00 | -- | 0.47 | -- |
|
Exceptional Items
|
-17.93 | 61.52 | -- | -- | -- |
|
Profit before Tax
|
-489.58 | 1,837.69 | 3.97 | 3.09 | -- |
|
Provision for Tax
|
-156.90 | 258.21 | 1.13 | 1.04 | -- |
|
Profit after Tax
|
-332.68 | 1,579.48 | 2.84 | 2.05 | -- |
Liabilities (₹ Cr)
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
-78.39 | 2,704.18 | 40.33 | 8.16 | -- |
|
Minority Interest
|
-15.52 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
147.64 | 1,520.80 | 7.33 | 1.19 | -- |
|
Current Liabilities
|
1,840.35 | 1,773.48 | 21.75 | 16.97 | -- |
|
Total Liabilities
|
2,149.37 | 6,022.66 | 69.41 | 26.51 | -- |
Assets (₹ Cr)
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
902.94 | 2,671.53 | 49.55 | 5.37 | -- |
|
Current Assets
|
991.13 | 3,326.93 | 19.86 | 20.95 | -- |
|
Total Assets
|
2,149.37 | 6,022.66 | 69.41 | 26.51 | -- |
|
Total Debt*
|
2,171.17 | 2,070.47 | 19.09 | 8.17 | -- |
|
Net Current Assets
|
-849.22 | 1,553.45 | -1.89 | 3.98 | -- |
|
Contingent Liabilities
|
266.85 | 79.85 | 0.70 | -- | -- |
Cashflow (₹ Cr)
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
133.21 | 1,532.40 | 3.99 | -- | -- |
|
Cash Flow from Investing Activities
|
-7.95 | 1,085.37 | -4.09 | -- | -- |
|
Cash from Financing Activities
|
-133.12 | -2,245.75 | 0.43 | -- | -- |
|
Net Cash Inflow / Outflow
|
-7.86 | 372.02 | 0.33 | 0.00 | -- |
Ratios
Profitability Ratios
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-12.70 | 42.17 | 11.29 | 29.13 | -- |
|
ROE (%)
|
-451.80 | 102.78 | 14.27 | 28.77 | -- |
|
ROA (%)
|
-16.34 | 25.78 | 4.14 | 8.50 | -- |
|
EBIT Margin (%)
|
-200.89 | 37.68 | 25.96 | 9.19 | -- |
|
Net Margin (%)
|
-363.91 | 27.89 | 7.66 | 3.67 | -- |
|
Cash Profit Margin (%)
|
-279.02 | 30.30 | 15.96 | 4.96 | -- |
Growth Ratios
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-94.83 | 28.94 | 6.60 | 63.77 | -- |
|
EBIT Growth (%)
|
12.25 | 53.27 | 5.26 | 21.99 | -- |
|
Net Profit Growth (%)
|
-9.15 | 427.46 | 12.54 | 52.02 | -- |
|
EPS Growth (%)
|
-5.01 | 364.85 | 12.54 | 52.02 | -- |
|
Book Value Growth (%)
|
-135.41 | 239.42 | 15.36 | 33.62 | -- |
Valuation Ratios
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Price / Earnings
|
0.00 | 12.71 | 0.00 | 0.00 | -- |
|
Price / Book Value
|
-0.35 | 9.26 | 0.00 | 0.00 | -- |
|
Dividend Yield (%)
|
0.00 | 0.25 | -- | -- | -- |
|
EV/EBITDA
|
-12.06 | 11.00 | 4.10 | 1.79 | -- |
|
Market Cap (₹ Cr)
|
28.53 | 21,979.56 | 0.00 | 0.00 | -- |
Solvency Ratios
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-26.89 | 0.77 | 0.47 | 1.00 | -- |
|
Short term debt to equity ratio
|
-21.22 | 0.07 | 0.24 | 0.67 | -- |
|
Current Ratio
|
0.54 | 1.88 | 0.91 | 1.23 | -- |
|
Quick Ratio
|
0.19 | 1.28 | 0.85 | 0.87 | -- |
|
Interest Coverage
|
-1.21 | 9.53 | 2.54 | 3.77 | -- |
Operating Efficiency Ratios
| Surya Pharmaceutical | Wockhardt | Rubicon Research | Acutaas Chemicals | Piramal Pharma | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
249.68 | 17.09 | 27.75 | 19.50 | -- |
|
Asset Turnover
|
0.05 | 0.92 | 0.54 | 2.47 | -- |
|
Receivable days
|
917.33 | 55.81 | 123.43 | 58.39 | -- |
|
Inventory Days
|
2,833.48 | 63.29 | 10.53 | 37.68 | -- |
|
Payable days
|
101.21 | 122.70 | -- | 93.41 | -- |
|
Cash Conversion Cycle
|
3,649.60 | -3.60 | -- | 2.66 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
